Tirzepatide postpartum: what TikTok skips over

What did @iamalmaramirez actually say?

In week three of using tirzepatide (she calls it "trisapatine"), the creator reports losing about 10.8 pounds in the first week, reaching nearly 12 pounds total by the time of filming. She acknowledges it was "a lot of water weight" early on. She also mentions getting her medication from a telehealth pharmacy called IVY Rx, describes the packaging and delivery process, notes mild constipation as her only side effect, and explains she prioritizes protein and hydration. She says she injects "50 units" in her arm rather than her stomach.

Worth flagging upfront: the video is tagged as a paid partnership with IVY Rx. That doesn't automatically make her claims wrong, but it does mean this is an advertisement, not a neutral testimonial. Viewers deserve to know that context before taking anything she says at face value.

Does the science back this up?

The rapid early weight loss she describes is plausible, though it's mostly water and glycogen, not fat. Tirzepatide's actual fat-loss results build over months, not one week. The SURMOUNT-1 trial showed real, significant results, but not at this speed.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that participants on the highest dose (15 mg weekly) lost an average of 20.9% of body weight over 72 weeks. That's the gold-standard data. The first-week number she cites is not representative of ongoing fat loss. Early weight loss on GLP-1 and GIP agonists typically reflects reduced caloric intake and water loss tied to glycogen depletion, not adipose tissue reduction. A 10.8-pound loss in seven days would require roughly a 37,800-calorie deficit, which is not physiologically realistic as fat loss alone.

Her instinct that it was "a lot of water weight" is correct. That self-awareness deserves some credit.

What did they get wrong (or right)?

She got the water weight caveat right. She got the protein priority right. She got the constipation disclosure right. Where the video gets murky is around dose communication and the implicit suggestion that fast early results are typical.

Mentioning "50 units" publicly is a problem. Tirzepatide dosing from compounding pharmacies is often expressed in units drawn from a vial, and the concentration can vary between compounders. What is 50 units from one pharmacy may not equal 50 units from another. Sharing a specific unit number without that context could lead a viewer to assume the same dose applies to them, which it does not. A licensed prescriber determines appropriate dosing based on individual patient history. No social media post should be a dosing reference.

The constipation disclosure is genuinely useful. Gastrointestinal side effects are the most commonly reported adverse events with tirzepatide, documented in both SURMOUNT-1 and SURPASS trial data. She doesn't overstate or understate it, and she's managing it reasonably with hydration.

The compounded medication framing is also worth scrutiny. Compounded tirzepatide is not FDA-approved. It is not the same as Zepbound or Mounjaro. The FDA has previously issued warnings about compounded versions of GLP-1 drugs, including dosing errors and quality inconsistencies. That distinction is absent from this video entirely.

What should you actually know?

If you're considering tirzepatide, the trial data is genuinely promising, but week-one results from a postpartum affiliate video are not the data you should be making decisions from. The SURMOUNT-1 results are robust. The first-week scale number in this video is not a reliable predictor of your outcome.

A few things this video skips that actually matter. Tirzepatide is not approved for use while breastfeeding. The creator mentions a postpartum journey in her hashtags, and that context raises a real clinical question that goes completely unaddressed. If she is breastfeeding, this is a significant safety gap. If she is not, that should be clarified, because the audience reading "postpartumjourney" may be breastfeeding themselves and may assume this medication is appropriate for that stage.

Additionally, compounded tirzepatide sits in a complicated regulatory space. The FDA placed semaglutide and tirzepatide on its shortage list, which temporarily permitted compounding, but that status has been updated. Anyone sourcing compounded tirzepatide should confirm current legal and safety status with a licensed provider, not a TikTok comment section.

Protein and hydration emphasis is solid, practical advice. Those are consistent with clinical recommendations for patients on GLP-1 class medications to preserve lean mass and manage side effects.